Nausea on Wegovy (semaglutide 2.4 mg): Week-by-Week Timeline of What to Expect

Does the label give a week-by-week nausea timeline?

No. The 44% figure comes from three double-blind, placebo-controlled trials that followed 2,116 adults on Wegovy 2.4 mg and 1,261 on placebo for up to 68 weeks, plus a 7-week off-drug follow-up [1]. It is a single number covering the whole treatment period, dose escalation included, so it does not show when nausea starts, when it peaks or when it eases. We found no published week-by-week breakdown of nausea on semaglutide 2.4 mg.

The escalation schedule the label sets

Wegovy injection is given once weekly, starting at 0.25 mg for weeks 1 to 4, then 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12 and 1.7 mg for weeks 13 to 16, with maintenance from week 17 [1]. The label says to follow this schedule to reduce the risk of gastrointestinal adverse reactions, and that if a dose is not tolerated during escalation, consider delaying escalation for 4 weeks [1]. For weight reduction the recommended maintenance dose is 2.4 mg, with 1.7 mg as the other maintenance option; adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may go to a maximum of 7.2 mg weekly [1].

How long the drug stays in the body

After an injection, semaglutide peaks 1 to 3 days later, and its elimination half-life is about 1 week, so it stays in the body for about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection [1]. These are drug-level figures; the label does not report how nausea changes across a dosing week or after the last dose.

What the trials reported instead

In the pooled 2.4 mg trials, nausea was the most common reaction at 44% versus 16% on placebo, followed by diarrhea (30% versus 16%), vomiting (24% versus 6%), constipation (24% versus 11%) and abdominal pain (20% versus 10%) [1]. Any gastrointestinal reaction occurred in 73% versus 47%, and severe gastrointestinal reactions in 4.1% versus 0.9% [1]. Nausea was the leading reason for stopping among the listed reactions: 1.8% versus 0.2%, against 6.8% versus 3.2% stopping for any adverse reaction [1].

Two 72-week trials compared 7.2 mg with 2.4 mg: nausea 39% on 7.2 mg, 35% on 2.4 mg and 13% on placebo; vomiting 22%, 16% and 6% [1].

What the label says to watch for

The label says gastrointestinal reactions can be severe and that Wegovy is not recommended in people with severe gastroparesis [1]. Postmarketing reports include ileus, intestinal obstruction and severe constipation with fecal impaction [1]. Acute pancreatitis has been reported; the label says to discontinue Wegovy if pancreatitis is suspected and describes persistent severe abdominal pain, sometimes radiating to the back, that may or may not come with nausea or vomiting [1].

Acute kidney injury from volume depletion occurred in 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with prior kidney impairment and during dose titration, often after gastrointestinal fluid loss [1]. Cholelithiasis was reported by 1.6% versus 0.7% and cholecystitis by 0.6% versus 0.2% [1].